Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both

William A. Briggs, Zu Hua Gao, Jing Jing Xing, Luis F. Gimenez, Milagros D. Samaniego, Paul J. Scheel, Michael J Choi, James F. Burdick

Research output: Contribution to journalArticle

Abstract

Although glucocorticoids and cyclosporine are frequently used to treat patients with various types of glomerulopathy, clinical responses to treatment vary considerably. Considerable interindividual heterogeneity in the suppressive effects of glucocorticoids on lymphocyte proliferation in vitro has been previously reported, suggesting that differences in the pharmacodynamic responsiveness of the immune system to these agents might be an important determinant of how well an individual patient responds to treatment. It also has been shown that methylprednisolone is significantly more suppressive than prednisolone. To identify cellular mechanisms by which these drugs act, a study of the suppressive effects of prednisolone, methylprednisolone, and cyclosporine on lymphocyte proliferation and the expression of the cell surface receptor for interleukin-2 (IL-2R) was conducted using phytohemagglutin-stimulated peripheral blood mononuclear cells (PBMCs) from 13 patients with glomerulopathy and 12 control subjects. Heterogeneity among individuals in both parameters of lymphocyte responsiveness to these drugs was again found, and the significantly greater suppressive effect of methylprednisolone was confirmed for both proliferation and IL-2R expression in patients and control subjects. Cyclosporine alone was moderately suppressive. For most individuals, the greatest degree of suppression occurred when cells were exposed to both cyclosporine and glucocorticoid. Further studies are being conducted to determine whether pretreatment assessment of in vitro lymphocyte responsiveness has any predictive value regarding therapeutic efficacy of each drug in individual patients and to identify of those patients likely to require a more intensive or multidrug immunosuppressive regimen.

Original languageEnglish (US)
Pages (from-to)931-937
Number of pages7
JournalJournal of Clinical Pharmacology
Volume36
Issue number10
StatePublished - Oct 1996

Fingerprint

Interleukin-2 Receptors
Cyclosporine
Glucocorticoids
Lymphocytes
Methylprednisolone
Prednisolone
Pharmaceutical Preparations
Cell Surface Receptors
Immunosuppressive Agents
Interleukin-2
Immune System
Blood Cells
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Briggs, W. A., Gao, Z. H., Xing, J. J., Gimenez, L. F., Samaniego, M. D., Scheel, P. J., ... Burdick, J. F. (1996). Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both. Journal of Clinical Pharmacology, 36(10), 931-937.

Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both. / Briggs, William A.; Gao, Zu Hua; Xing, Jing Jing; Gimenez, Luis F.; Samaniego, Milagros D.; Scheel, Paul J.; Choi, Michael J; Burdick, James F.

In: Journal of Clinical Pharmacology, Vol. 36, No. 10, 10.1996, p. 931-937.

Research output: Contribution to journalArticle

Briggs, WA, Gao, ZH, Xing, JJ, Gimenez, LF, Samaniego, MD, Scheel, PJ, Choi, MJ & Burdick, JF 1996, 'Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both', Journal of Clinical Pharmacology, vol. 36, no. 10, pp. 931-937.
Briggs WA, Gao ZH, Xing JJ, Gimenez LF, Samaniego MD, Scheel PJ et al. Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both. Journal of Clinical Pharmacology. 1996 Oct;36(10):931-937.
Briggs, William A. ; Gao, Zu Hua ; Xing, Jing Jing ; Gimenez, Luis F. ; Samaniego, Milagros D. ; Scheel, Paul J. ; Choi, Michael J ; Burdick, James F. / Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both. In: Journal of Clinical Pharmacology. 1996 ; Vol. 36, No. 10. pp. 931-937.
@article{fcbf61e0ec1c4f1d88eaf07f72ad9bc3,
title = "Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both",
abstract = "Although glucocorticoids and cyclosporine are frequently used to treat patients with various types of glomerulopathy, clinical responses to treatment vary considerably. Considerable interindividual heterogeneity in the suppressive effects of glucocorticoids on lymphocyte proliferation in vitro has been previously reported, suggesting that differences in the pharmacodynamic responsiveness of the immune system to these agents might be an important determinant of how well an individual patient responds to treatment. It also has been shown that methylprednisolone is significantly more suppressive than prednisolone. To identify cellular mechanisms by which these drugs act, a study of the suppressive effects of prednisolone, methylprednisolone, and cyclosporine on lymphocyte proliferation and the expression of the cell surface receptor for interleukin-2 (IL-2R) was conducted using phytohemagglutin-stimulated peripheral blood mononuclear cells (PBMCs) from 13 patients with glomerulopathy and 12 control subjects. Heterogeneity among individuals in both parameters of lymphocyte responsiveness to these drugs was again found, and the significantly greater suppressive effect of methylprednisolone was confirmed for both proliferation and IL-2R expression in patients and control subjects. Cyclosporine alone was moderately suppressive. For most individuals, the greatest degree of suppression occurred when cells were exposed to both cyclosporine and glucocorticoid. Further studies are being conducted to determine whether pretreatment assessment of in vitro lymphocyte responsiveness has any predictive value regarding therapeutic efficacy of each drug in individual patients and to identify of those patients likely to require a more intensive or multidrug immunosuppressive regimen.",
author = "Briggs, {William A.} and Gao, {Zu Hua} and Xing, {Jing Jing} and Gimenez, {Luis F.} and Samaniego, {Milagros D.} and Scheel, {Paul J.} and Choi, {Michael J} and Burdick, {James F.}",
year = "1996",
month = "10",
language = "English (US)",
volume = "36",
pages = "931--937",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both

AU - Briggs, William A.

AU - Gao, Zu Hua

AU - Xing, Jing Jing

AU - Gimenez, Luis F.

AU - Samaniego, Milagros D.

AU - Scheel, Paul J.

AU - Choi, Michael J

AU - Burdick, James F.

PY - 1996/10

Y1 - 1996/10

N2 - Although glucocorticoids and cyclosporine are frequently used to treat patients with various types of glomerulopathy, clinical responses to treatment vary considerably. Considerable interindividual heterogeneity in the suppressive effects of glucocorticoids on lymphocyte proliferation in vitro has been previously reported, suggesting that differences in the pharmacodynamic responsiveness of the immune system to these agents might be an important determinant of how well an individual patient responds to treatment. It also has been shown that methylprednisolone is significantly more suppressive than prednisolone. To identify cellular mechanisms by which these drugs act, a study of the suppressive effects of prednisolone, methylprednisolone, and cyclosporine on lymphocyte proliferation and the expression of the cell surface receptor for interleukin-2 (IL-2R) was conducted using phytohemagglutin-stimulated peripheral blood mononuclear cells (PBMCs) from 13 patients with glomerulopathy and 12 control subjects. Heterogeneity among individuals in both parameters of lymphocyte responsiveness to these drugs was again found, and the significantly greater suppressive effect of methylprednisolone was confirmed for both proliferation and IL-2R expression in patients and control subjects. Cyclosporine alone was moderately suppressive. For most individuals, the greatest degree of suppression occurred when cells were exposed to both cyclosporine and glucocorticoid. Further studies are being conducted to determine whether pretreatment assessment of in vitro lymphocyte responsiveness has any predictive value regarding therapeutic efficacy of each drug in individual patients and to identify of those patients likely to require a more intensive or multidrug immunosuppressive regimen.

AB - Although glucocorticoids and cyclosporine are frequently used to treat patients with various types of glomerulopathy, clinical responses to treatment vary considerably. Considerable interindividual heterogeneity in the suppressive effects of glucocorticoids on lymphocyte proliferation in vitro has been previously reported, suggesting that differences in the pharmacodynamic responsiveness of the immune system to these agents might be an important determinant of how well an individual patient responds to treatment. It also has been shown that methylprednisolone is significantly more suppressive than prednisolone. To identify cellular mechanisms by which these drugs act, a study of the suppressive effects of prednisolone, methylprednisolone, and cyclosporine on lymphocyte proliferation and the expression of the cell surface receptor for interleukin-2 (IL-2R) was conducted using phytohemagglutin-stimulated peripheral blood mononuclear cells (PBMCs) from 13 patients with glomerulopathy and 12 control subjects. Heterogeneity among individuals in both parameters of lymphocyte responsiveness to these drugs was again found, and the significantly greater suppressive effect of methylprednisolone was confirmed for both proliferation and IL-2R expression in patients and control subjects. Cyclosporine alone was moderately suppressive. For most individuals, the greatest degree of suppression occurred when cells were exposed to both cyclosporine and glucocorticoid. Further studies are being conducted to determine whether pretreatment assessment of in vitro lymphocyte responsiveness has any predictive value regarding therapeutic efficacy of each drug in individual patients and to identify of those patients likely to require a more intensive or multidrug immunosuppressive regimen.

UR - http://www.scopus.com/inward/record.url?scp=0029846870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029846870&partnerID=8YFLogxK

M3 - Article

C2 - 8930780

AN - SCOPUS:0029846870

VL - 36

SP - 931

EP - 937

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -